Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

BOSTON, November 04, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report).

Vertex Pharmaceuticals (VRTX) closed at $465.08 in the latest trading session, marking a +0.48% move from the prior day. This move outpaced the S&P 500's daily gain of 0.42%. Meanwhile ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

While there are several candidates to make the next stock split announcement, Vertex Pharmaceuticals (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4. Just because a stock ...